dc.contributor.author
Ertaş, Ragıp
dc.contributor.author
Hawro, Tomasz
dc.contributor.author
Altrichter, Sabine
dc.contributor.author
Özyurt, Kemal
dc.contributor.author
Erol, Kemal
dc.contributor.author
Ketenci Ertaş, Şule
dc.contributor.author
Maurer, Marcus
dc.date.accessioned
2022-05-25T08:42:11Z
dc.date.available
2022-05-25T08:42:11Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/34104
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-33822
dc.rights.uri
https://creativecommons.org/licenses/by-nc/4.0/
dc.subject
Anti-Allergic Agents
en
dc.subject
Chronic Urticaria
en
dc.subject
Histamine Antagonists
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1111/all.14033
dcterms.bibliographicCitation.journaltitle
Allergy
dcterms.bibliographicCitation.number
2
dcterms.bibliographicCitation.originalpublishername
Wiley
dcterms.bibliographicCitation.pagestart
468
dcterms.bibliographicCitation.pageend
470
dcterms.bibliographicCitation.volume
75
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
DEAL Wiley
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
31469912
dcterms.isPartOf.issn
0105-4538
dcterms.isPartOf.eissn
1398-9995
